Univax Biologics Inc. said that it has added a fourth product, astandard immunoglobulin, to its license and distributionagreement with Farma Biogini S.p.A.
In January, the Rockville, Md., company (NASDAQ:UNVX)licensed three hyperimmune IGIVs from the Italian plasmafractionator. The agreement gives Univax exclusive U.S. andCanadian distribution rights to the four products uponregulatory approvals.
The standard immunoglobulin consists of antibody-rich plasma,but has no specificity for a particular disease. The product isscheduled to begin Phase I U.S. trials by the end of this year totreat hypogammaglobulin anemia in children. Such children areborn with a B cell deficiency that makes them unable toproduce sufficient quantities of gammaglobulin.
The three hyperimmune IGIVs are targeted atcytomegalovirus, hepatitis B and varicella-zoster.
Univax shares closed down 25 cents on Wednesday at $8.25. --KB
(c) 1997 American Health Consultants. All rights reserved.